지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background: Late-life depression (LLD) is one of the most common psychiatric disorders. However, LLD is often undetected or inadequately treated by clinicians. This review summarizes the recent research on pharmacotherapy for LLD, updates information on monotherapy using recommended antidepressants, and discusses the clinical features and diagnostic criteria for LLD.
Current Concepts: The diagnostic criteria for depression in both elderly and young adults are identical. Clinical features of the elderly with depression more likely include more comorbid medical conditions and cognitive impairment than those of young adults. Depression in the elderly tends to have a more chronic course with frequent recurrences or relapses.
Discussion and Conclusion: The current pharmacological treatment guidelines for LLD recommend the use of selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor, bupropion, mirtazapine, and vortioxetine as first-line medications. SSRIs, among them, are recommended first because they present fewer serious adverse effects and more clinical evidence than those of other antidepressants. Before starting antidepressant treatment for LLD, clinicians should consider patients’ comorbid medical conditions, drug interactions, possible adverse effects of antidepressants, and polypharmacy. The starting dose of antidepressants for elderly patients should be half of that prescribed for young adults to minimize the adverse effects; however, most elderly patients need the same antidepressant doses as that prescribed for young patients. After remission, a 1-year maintenance treatment is required to prevent recurrence or relapse of LLD.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
새로운 우울증 치료 약물
생물정신의학
2016 .01
-
항우울제 중단 증후군
신경정신의학
2024 .05
-
증상 중심의 항우울제 선택
대한의사협회지
2020 .01
-
Scoliosis Caused by Limb-Length Discrepancy in Children
Asian Spine Journal
2020 .01
-
우울증과 항우울작용에 관한 p11(S100A10)의 역할
생물정신의학
2016 .01
-
유도된 다리길이 차이가 안정성한계와 정적 자세균형에 미치는 영향
PNF and movement
2018 .01
-
Use of Serum Biomarkers to Aid Antidepressant Selection in Depressive Patients
Clinical Psychopharmacology and Neuroscience
2024 .02
-
A Critical View on New and Future Antidepressants
Clinical Psychopharmacology and Neuroscience
2024 .05
-
한국형 우울장애 약물치료 알고리듬 2017(III) : 유지치료
우울조울병
2017 .01
-
보행 중 인위적 다리길이 차이에 따른 3차원적 골반 가동범위의 특성
대한통합의학회지
2019 .01
-
Transcriptional anatomy of the antidepressant actions in the CNS
한국실험동물학회 학술발표대회 논문집
2016 .08
-
항우울제로 새롭게 등장한 ‘남용 물질’ - 약리학적 기전, 항우울 효과, 오남용 가능성에 대한 고찰
신경정신의학
2022 .11
-
주요우울장애 노인 환자의 항우울제 복약이행도 연구
한국임상약학회지
2023 .03
-
Antidepressants in Spine Surgery: A Systematic Review to Determine Benefits and Risks
Asian Spine Journal
2019 .01
-
The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology
PSYCHIATRY INVESTIGATION
2018 .01
-
The Effects of Simulated Mild Leg Length Discrepancy on Gait Parameters and Trunk Acceleration
한국전문물리치료학회지
2018 .01
-
Comparison of the Effect of Insole Correction on Three-Dimensional Knee Joint Moments during Gait in Standing Workers with Leg Length Discrepancy
근골격계과학기술학회
2021 .01
-
Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder
Clinical Psychopharmacology and Neuroscience
2018 .01
-
Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder
PSYCHIATRY INVESTIGATION
2016 .01
-
폐암 환자의 항우울제 처방현황과 관련 요인 분석
한국임상약학회지
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0